Affordable Access

The role of platelet growth factors in cancer therapy.

Authors
  • Clarke, K
  • Basser, R L
Type
Published Article
Journal
Stem cells (Dayton, Ohio)
Publication Date
Jan 01, 1996
Volume
14 Suppl 1
Pages
274–280
Identifiers
PMID: 11012231
Source
Medline
License
Unknown

Abstract

The use of myeloid growth factors has markedly reduced the complications of chemotherapy-induced neutropenia, however, abrogation of severe thrombocytopenia remains a major clinical problem. Platelet transfusions remain the standard method of preventing or treating thrombocytopenia but are associated with a variety of complications and are a limited resource. A number of cytokines have been clinically investigated for their thrombopoietic activity, the most promising of which is the recently cloned ligand to the hematopoietic growth factor receptor, c-Mpl. The c-Mpl ligand, also referred to as thrombopoietin, megakaryocyte growth and development factor (MGDF) and megapoietin, is a potent lineage-specific agent that promotes growth and maturation of megakaryocytes and their progenitors. It holds promise for clinical use in the treatment of iatrogenic or disease-associated bone marrow failure states and possibly in syndromes of excessive platelet consumption. Early clinical trials assessing the safety and activity of recombinant human MGDF are now underway.

Report this publication

Statistics

Seen <100 times